Skip to main content
SpringerLink
Log in

Novel Formulation Approaches for Treatment of Ebola Virus

  • Chapter
  • First Online:
Viral Drug Delivery Systems

Abstract

The segment of the United Nations that deals with the medical aspects of all the different parts of the world, the World Health Organization, on the 3rd of May 2021, professed the ongoing Ebola outbreak to be over. Ebola virus is acknowledged to be the causative agent of Ebola viral disease (EVD) or Ebola fever, which is of an hemorrhagic nature, a viral hemorrhagic disease found in humans in addition to some arboreal primates. The diagnosis is made using recognition of viral RNA through a reverse transcriptase-polymerase chain reaction in real time and even through fast diagnostic tests, the basis of which are detection of antigens using an enzyme-linked immunosorbent assay. Although vaccines are still important in reducing deaths due to EVD, other strategic approaches to working for its prevention and management are required. Several patented agents, biotherapeutics, etc., are required for prophylactic or therapeutic purposes. This article deals with different medicines and vaccines, etc., which are emerging or alternatives to the treatment of EVD. A shift in paradigm toward improvement in medical and clinical health structures had a quick impact on EVD containment while also laying the groundwork for introducing new medicines and therapies to the afflicted countries once the said medicines combined with the therapies became obtainable.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Abbreviations

EBOV:

Ebola virus

EVD:

Ebola viral disease

GP:

Glycoprotein

NP:

Nucleoprotein

References

  1. Baseler L, Chertow DS, Johnson KM, et al. The pathogenesis of Ebola virus disease. Ann Rev Pathol. 2017;12:387–418.

    Article  CAS  Google Scholar 

  2. Marzi A, Mire CE. Current Ebola virus vaccine progress. BioDrugs. 2019;33(1):9–14.

    Article  CAS  PubMed  Google Scholar 

  3. Jadav SS, Kumar A, Ahsan MJ, et al. Ebola virus: current and future perspectives. Infect Disord Drug Targets. 2015;15(1):20–31.

    Article  CAS  PubMed  Google Scholar 

  4. Martines RB, Ng DL, Greer PW, et al. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol. 2015;235(2):153–74.

    Article  CAS  PubMed  Google Scholar 

  5. Reynolds P, Marzi A. Ebola and Marburg virus vaccines. Virus Genes. 2017;53(4):501–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kortepeter MG, Dierberg K, Shenoy ES, et al. Marburg virus disease: a summary for clinicians. Int J Infect Dis. 2020;99:233–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Martell HJ, Masterson SG, McGreig JE, et al. Is the Bombali virus pathogenic in humans? Bioinformatics. 2019;35(19):3553–8.

    Article  CAS  PubMed  Google Scholar 

  8. Muñoz LS, Garcia MA, Gordon-Lipkin E, et al. Emerging viral infections and their impact on the global burden of neurological disease. Semin Neurol. 2018;38(2):163–75.

    Article  PubMed  Google Scholar 

  9. Siddharta A, Pfaender S, Vielle NJ, et al. Virucidal activity of World Health Organization-recommended formulations against enveloped viruses, including Zika, Ebola, and Emerging Coronaviruses. Int J Infect Dis. 2017;215(6):902–6.

    Article  CAS  Google Scholar 

  10. Thys S, Boelaert M. The origin of Ebola: biomedical approach versus popular interpretations in Macenta. Guinea Sante Publique. 2017;29(4):497–507.

    Article  PubMed  Google Scholar 

  11. Shoman H, Karafillakis E, Rawaf S. The link between the West African Ebola outbreak and health systems in Guinea, Liberia and Sierra Leone: a systematic review. Glob Health. 2017;13(1):1.

    Article  Google Scholar 

  12. Formenty P, Boesch C, Wyers M, et al. Ebola virus outbreak among wild chimpanzees living in a rain forest of Côte d’Ivoire. Int J Infect Dis. 1999;179(Suppl 1):S120–6.

    Article  Google Scholar 

  13. Holmes EC, Dudas G, Rambaut A, et al. The evolution of Ebola virus: insights from the 2013-2016 epidemic. Nature. 2016;538(7624):193–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Yu C, Li S, Zhang X, et al. MARCH8 inhibits Ebola virus glycoprotein, human immunodeficiency virus type 1 envelope glycoprotein, and Avian Influenza Virus H5N1 Hemagglutinin maturation. mBio. 2020;11(5):e01882–20.

    Google Scholar 

  15. Jacob ST, Crozier I, Fischer WA 2nd, et al. Ebola virus disease. Nat Rev Dis Primers. 2020;6(1):13.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Wan W, Kolesnikova L, Clarke M, et al. Structure and assembly of the Ebola virus nucleocapsid. Nature. 2017;551(7680):394–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Wong G, Zhang Z, He S, et al. Marburg and Ravn virus infections do not cause observable disease in Ferrets. Int J Infect Dis. 2018;218(suppl_5): S471–4.

    Google Scholar 

  18. Alazard-Dany N, Ottmann Terrangle M, Volchkov V. Ebola and Marburg viruses: the humans strike back. Med Sci (Paris). 2006;22(4):405–10.

    Article  PubMed  Google Scholar 

  19. Charbe NB, Amnerkar ND, Ramesh B, et al. Small interfering RNA for cancer treatment: overcoming hurdles in delivery. Acta Pharm Sin B. 2020;10(11):2075–109.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. De Clercq E. Interferon: ten stories in one. A short review of some of the highlights in the history of an almost quinquagenarian. Acta Microbiol Immunol Hung. 2005;52(3–4):273–89.

    PubMed  Google Scholar 

  21. Zhu W, Banadyga L, Emeterio K, et al. The roles of Ebola virus soluble glycoprotein in replication, pathogenesis, and countermeasure development. Viruses. 2019;11(11):999.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Dhama K, Karthik K, Khandia R, et al. Advances in designing and developing vaccines, drugs, and therapies to counter Ebola virus. Front Immunol. 2018;9:1803.

    Article  PubMed  PubMed Central  Google Scholar 

  23. van Griensven J, De Weiggheleire A, Delamou A, et al. The use of Ebola convalescent plasma to treat Ebola virus disease in resource-constrained settings: a perspective from the field. Clin Infect Dis. 2016;62(1):69–74.

    Article  PubMed  Google Scholar 

  24. Marcinkiewicz J, Bryniarski K, Nazimek K. Ebola haemorrhagic fever virus: pathogenesis, immune responses, potential prevention. Folia Med Cracov. 2014;54(3):39–48.

    PubMed  Google Scholar 

  25. Shayan S, Bokaean M, Shahrivar MR, et al. Crimean-Congo hemorrhagic fever. Lab Med. 2015;46(3):180–9.

    Article  PubMed  Google Scholar 

  26. Cole E, Gillespie S, Vulliamy P, et al. Multiple organ dysfunction after trauma. Br J Surg. 2020;107(4):402–12.

    Article  CAS  PubMed  Google Scholar 

  27. Möller MN, Rios N, Trujillo M, et al. Detection and quantification of nitric oxide-derived oxidants in biological systems. J Biol Chem. 2019;294(40):14776–802.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Malvy D, McElroy AK, de Clerck H, et al. Ebola virus disease. Lancet. 2019;393(10174):936–48.

    Article  PubMed  Google Scholar 

  29. Furuyama W, Marzi A. Ebola virus: pathogenesis and countermeasure development. Annu Rev Virol. 2019;6(1):435–58.

    Article  CAS  PubMed  Google Scholar 

  30. Takada A. Ebola vaccine and treatment. Uirusu. 2015;65(1):61–70.

    Article  CAS  PubMed  Google Scholar 

  31. Matz KM, Marzi A, Feldmann H. Ebola vaccine trials: progress in vaccine safety and immunogenicity. Expert Rev Vaccines. 2019;18(12):1229–42.

    Article  CAS  PubMed  Google Scholar 

  32. Lu DY, Wu HY, Yarla NS, et al. Ebola therapeutic study and future directions. Infect Disord Drug Targets. 2019;19(1):17–29.

    Article  CAS  PubMed  Google Scholar 

  33. Muñoz-Fontela C, McElroy AK. Ebola virus disease in humans: pathophysiology and immunity. Curr Top Microbiol Immunol. 2017;411:141–69.

    PubMed  PubMed Central  Google Scholar 

  34. Kang YL, Chou YY, Rothlauf PW, et al. Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117(34):20803–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. King LB, Milligan JC, West BR, et al. Achieving cross-reactivity with pan-ebolavirus antibodies. Curr Opin Virol. 2019;34:140–8.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Sharma A, Castellani RJ, Smith MA, et al. 5-Hydroxytryptophan: a precursor of serotonin influences regional blood-brain barrier breakdown, cerebral blood flow, brain edema formation, and neuropathology. Int Rev Neurobiol. 2019;146:1–44.

    Article  CAS  PubMed  Google Scholar 

  37. Arao Y, Korach KS. Transactivation Function-1-mediated partial agonist activity of selective estrogen receptor modulator requires homo-dimerization of the estrogen receptor α ligand binding domain. Int J Mol Sci. 2019;20(15):3718.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Tambo E, Chengho CF, Ugwu CE, et al. Rebuilding transformation strategies in post-Ebola epidemics in Africa. Infect Dis Poverty. 2017;6(1):71.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Clarke DK, Xu R, Matassov D, et al. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial. Lancet Infect Dis. 2020 Apr;20(4):455–66.

    Article  CAS  PubMed  Google Scholar 

  40. O’Donnell K, Marzi A. The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms. Expert Rev Vaccines. 2020;19(3):267–77.

    Article  PubMed  Google Scholar 

  41. Chalkias S, Gorham JM, Mazaika E, et al. ViroFind: a novel target-enrichment deep-sequencing platform reveals a complex JC virus population in the brain of PML patients. PLoS One. 2018;13(1):e0186945.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Warfield KL, Posten NA, Swenson DL, et al. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis. 2007;196(Suppl 2):S421–9.

    Article  CAS  PubMed  Google Scholar 

  43. Yadav T, Srivastava N, Mishra G, et al. Recombinant vaccines for COVID-19. Hum Vaccin Immunother. 2020;16(12):2905–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Martins KA, Jahrling PB, Bavari S, Kuhn JH. Ebola virus disease candidate vaccines under evaluation in clinical trials. Expert Rev Vaccines. 2016 Sep 1;15(9):1101–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. De Clercq E. Ebola virus (EBOV) infection: therapeutic strategies. Biochem Pharmacol. 2015;93(1):1–10.

    Article  PubMed  Google Scholar 

  46. Menicucci AR, Jankeel A, Feldmann H, et al. Antiviral innate responses induced by VSV-EBOV vaccination contribute to rapid protection. mBio. 2019;10(3):e00597–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Taylor R, Kotian P, Warren T, et al. BCX4430 - a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public Health. 2016;9(3):220–6.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Johnson JC, Martinez O, Honko AN, et al. Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells. Antivir Res. 2014;107:102–9.

    Article  PubMed  Google Scholar 

  49. Kofman A, Linderman S, Su K, et al. Characteristics of Ebola virus disease survivor blood and semen in Liberia: serology and RT-PCR. Clin Infect Dis. 2020:ciaa1331.

    Google Scholar 

  50. Hou Q, Zhang L. Biomimetic Design of Peptide Neutralizer of Ebola virus with molecular simulation. Langmuir. 2020;36(7):1813–21.

    Article  CAS  PubMed  Google Scholar 

  51. Xu C, Katyal N, Nesterova T, et al. Molecular determinants of Ebola nucleocapsid stability from molecular dynamics simulations. Chem Phys. 2020;153(15):155102.

    CAS  Google Scholar 

  52. Hume A, Mühlberger E. Marburg virus viral protein 35 inhibits protein Kinase R activation in a cell type-specific manner. J Infect Dis. 2018;218(suppl_5): S403–8.

    Google Scholar 

  53. Banerjee A, Mitra P. Ebola virus VP35 protein: modeling of the tetrameric structure and an analysis of its interaction with human PKR. J Proteome Res. 2020;19(11):4533–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, School of Pharmacy & Technology Management, SVKM’S NMIMS Deemed-to-be University, Shirpur, Maharashtra, India

    Sankha Bhattacharya & Shambhavi Singh

  2. Department of Microbiology, Tripura University, Agartala, Tripura, India

    Sambuddha Chakraborty

  3. Department of Pharmaceutics and Pharmaceutical Technology, Shree S K Patel College of Pharmaceutical Education and Research, Ganpat University, Mahesana, Gujarat, India

    Bhupendra G. Prajapati

  4. Department of Pharmaceutical Sciences, Mercer University College of Pharmacy, Atlanta, GA, USA

    Mahavir Chougule

  5. Nootan Pharmacy College, Sankalchand Patel University, Mehsana, Gujarat, India

    Jayvadan K. Patel

Authors
  1. Sankha Bhattacharya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shambhavi Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sambuddha Chakraborty
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bhupendra G. Prajapati
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mahavir Chougule
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jayvadan K. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. CapnoPharm GmbH, Tübingen, Germany

    Ranjita Shegokar

  2. Taneja College of Pharmacy, University of South Florida, Tampa, FL, USA

    Yashwant Pathak

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bhattacharya, S., Singh, S., Chakraborty, S., Prajapati, B.G., Chougule, M., Patel, J.K. (2023). Novel Formulation Approaches for Treatment of Ebola Virus. In: Shegokar, R., Pathak, Y. (eds) Viral Drug Delivery Systems. Springer, Cham. https://doi.org/10.1007/978-3-031-20537-8_7

Download citation

Publish with us

Policies and ethics

Search

Navigation